Human Antibodies Protect against COVID-19 in Animal Study

  • Author: ChemistryViews.org
  • Published: 20 June 2020
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA
  • Source / Publisher: Science/American Association for the Advancement of Science
thumbnail image: Human Antibodies Protect against COVID-19 in Animal Study

The worldwide outbreak of the respiratory disease COVID-19 is caused by the coronavirus SARS-CoV-2. Treatment options for COVID-19 are sparse, so far. The development of effective treatments and vaccines is of great importance. One option is the use of antibodies from recovered patients. Such antibodies target SARS-CoV-2 and could be used to both prevent and treat infections with the virus. However, the blood of recovered patients is a limited resource and, for broad use, effective antibodies need to be identified and mass-produced.


Devin Sok, Joseph G. Jardine, The Scripps Research Institute, La Jolla, CA, USA, and International AIDS Vaccine Initiative (IAVI), New York, USA, Dennis R. Burton, The Scripps Research Institute and Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology (MIT) and Harvard University, Cambridge, MA, USA, and colleagues have identified potent neutralizing antibodies (nAbs) in blood samples of patients who had recovered from COVID-19. The team collected samples from 17 patients and tested their plasma for binding to SARS-CoV-2 proteins. They also tested the samples for their protective effect on a cancer cell line that expresses the ACE2 receptor, which the virus uses to enter cells. Eight promising samples were selected for antibody isolation.


The team found several thousand different antibody-producing B cells in the samples, each of which produced a different antibody. The team used gene sequences from these cells to produce antibodies and selected the most active ones for further evaluation. The team found several potent nAbs that could block the virus from entering test cells, even at very low concentrations. They achieve this by binding to the receptor binding domain (RBD) that is part of the coronavirus' spike protein, and thus, preventing the virus from binding to ACE2. The team also performed a study in hamsters and found that the nAbs protected the animals against heavy viral exposure.



Also of Interest

  • Collection: SARS-CoV-2 Virus
    What we know about the new coronavirus and COVID-19
  • LitCovid
    Curated literature hub for tracking up-to-date scientific information about COVID-19
  • Many publishers and other entities have signed a joint statement to ensure that COVID-19 research findings and data are shared rapidly and openly

 

 

Article Views: 635

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more


CONNECT:

ChemistryViews.org on Facebook

ChemistryViews.org on Twitter ChemistryViews.org on YouTube ChemistryViews.org on LinkedIn Sign up for our free newsletter


Magazine of Chemistry Europe (16 European Chemical Societies)published by Wiley-VCH